Streptokinase in central retinal vein occlusion: a controlled clinical trial.
Forty patients with central retinal vein occlusion were allocated at random either to a treatment group given streptokinase followed by anticoagulatns or to a control group given no specific treatment. The two groups, which were each of 20 patients, were broadly similar in respect of clinical and laboratory values and similar in their initial visual acuity. At follow-up ("final" vision) the visual acuity in the treated group was significantly better than in the untreated group. Only one treated patient developed thrombotic glaucoma compared with four controls. Streptokinase may, however, have been responsible for vitreous haemorrhage (and permanent loss of vision) in three patients and hence probably has only a limited role in the treatment of central retinal vein occlusion.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003251:Constriction, Pathologic; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012169:Retinal Vein; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000188:drug therapy*; D014792:Visual Acuity; D014822:Vitreous Body
D013300:Streptokinase